SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.

Summary

Across 10 randomized trials (n=70,361), SGLT2 inhibitors reduced CKD progression by 38% (HR 0.62) irrespective of baseline eGFR or albuminuria, including in stage 4 CKD and minimal albuminuria. They also attenuated annual eGFR decline and reduced kidney failure risk. These findings support routine SGLT2 use across the kidney function spectrum in patients with type 2 diabetes, CKD, or heart failure.

Key Findings

• CKD progression reduced with SGLT2 inhibitors (HR 0.62; 95% CI 0.57-0.68).
• Benefit consistent across eGFR strata including <30 mL/min/1.73 m2 (P for trend=.16).
• Benefit consistent across albuminuria strata including ≤30 mg/g (P for trend=.49).
• Annual eGFR decline attenuated and kidney failure risk reduced (HR 0.66).

Clinical Implications

Initiate SGLT2 inhibitors broadly for patients with T2D, CKD, or heart failure to slow CKD progression, even with eGFR <30 mL/min/1.73 m2 or minimal albuminuria, unless contraindicated. Monitor eGFR trajectory but expect slower decline.

Limitations

• Heterogeneity in trial populations and follow-up durations may influence effect size estimates.
• Limited granularity for very advanced CKD subgroups beyond trial inclusion criteria.

Future Directions

Head-to-head comparisons within advanced CKD and low-albuminuria phenotypes; implementation studies to optimize uptake and address safety in very low eGFR.